Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:33:38.182Z.
Calculation as of: 2026-10-06T17:33:38.182Z.
Quote observation: 2026-10-06T16:49:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ac2c7a41ad5640622b079511a65f3d79aa9aa97fd30809e3a9f0c7038551df0a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$18.67M
Price/FCF Ratio
N/A
TTM Avg
126.35
3Y Avg
822.33
5Y Avg
822.33
Market Cap
$17.87M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| P3 Health Partners Inc. (PIII) | $19.67M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.43M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $19.51M | N/A | 278.20 | 278.20 | 278.20 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.67M | N/A | 126.35 | 822.33 | 822.33 |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.87M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $21.24M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $21.03M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.58M | N/A | 14.41 | 40.25 | 40.25 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.23M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
